Published in Rheumatology (Oxford) on November 23, 2004
First update of the international ASAS consensus statement for the use of anti-TNF agents in patients with ankylosing spondylitis. Ann Rheum Dis (2005) 2.21
Magnetic resonance imaging of the spine and the sacroiliac joints in ankylosing spondylitis and undifferentiated spondyloarthritis during treatment with etanercept. Ann Rheum Dis (2005) 1.21
Structural damage in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: traditional views, novel insights gained from TNF blockade, and concepts for the future. Arthritis Res Ther (2011) 1.17
How early should ankylosing spondylitis be treated with tumour necrosis factor blockers? Ann Rheum Dis (2005) 1.09
A systematic MEDLINE analysis of therapeutic approaches in ankylosing spondylitis. Rheumatol Int (2009) 0.98
[Spondylarthritides]. Z Rheumatol (2006) 0.95
Economic considerations of the treatment of ankylosing spondylitis. Am J Med Sci (2012) 0.93
Long-term safety and efficacy of etanercept in the treatment of ankylosing spondylitis. Patient Prefer Adherence (2013) 0.92
Physical function, disease activity, and health-related quality-of-life outcomes after 3 years of adalimumab treatment in patients with ankylosing spondylitis. Arthritis Res Ther (2009) 0.91
Long-term outcome of patients with active ankylosing spondylitis with etanercept-sustained efficacy and safety after seven years. Arthritis Res Ther (2013) 0.90
A 2-year comparative open label randomized study of efficacy and safety of etanercept and infliximab in patients with ankylosing spondylitis. Rheumatol Int (2009) 0.89
Multicenter validation of the value of BASFI and BASDAI in Chinese ankylosing spondylitis and undifferentiated spondyloarthropathy patients. Rheumatol Int (2009) 0.85
Safe re-administration of tumor necrosis factor-alpha (TNFα) inhibitors in patients with rheumatoid arthritis or ankylosing spondylitis who developed active tuberculosis on previous anti-TNFα therapy. J Korean Med Sci (2013) 0.85
The use of low-dose etanercept as an alternative therapy for treatment of ankylosing spondylitis: a case series. Rheumatol Int (2011) 0.83
Thalidomide reduces recurrence of ankylosing spondylitis in patients following discontinuation of etanercept. Rheumatol Int (2012) 0.83
Etanercept in the treatment of ankylosing spondylitis: a meta-analysis of randomized, double-blind, placebo-controlled clinical trials, and the comparison of the Caucasian and Chinese population. Eur J Orthop Surg Traumatol (2012) 0.82
Extended dosing of etanercept 25 mg can be effective in patients with ankylosing spondylitis: a retrospective analysis. Clin Rheumatol (2010) 0.81
Long-term safety and efficacy of infliximab for the treatment of ankylosing spondylitis. Ther Clin Risk Manag (2015) 0.80
Population pharmacokinetics of rhTNFR-Fc in healthy Chinese volunteers and in Chinese patients with Ankylosing spondylitis. Acta Pharmacol Sin (2010) 0.79
Low doses of etanercept can be effective to maintain remission in ankylosing spondylitis patients. Clin Rheumatol (2013) 0.79
Reliability and validity of the Italian version of the Chronic Pain Grade questionnaire in patients with musculoskeletal disorders. Clin Rheumatol (2006) 0.78
A survey of inclusion of the time element when reporting adverse effects in randomised controlled trials of cyclo-oxygenase-2 and tumour necrosis factor alpha inhibitors. Ann Rheum Dis (2006) 0.77
Spondyloarthritides: evolving therapies. Arthritis Res Ther (2010) 0.77
Anti-TNF Therapy in Ankylosing Spondylitis: Insights for the Clinician. Ther Adv Musculoskelet Dis (2010) 0.77
Crohn's disease unmasked following etanercept treatment for ankylosing spondylitis. BMJ Case Rep (2013) 0.77
Safety and clinical responses in ankylosing spondylitis after three months of etanercept therapy. J Korean Med Sci (2008) 0.77
Update on the use of etanercept across a spectrum of rheumatoid disorders. Biologics (2008) 0.76
Bioboosters in the treatment of rheumatic diseases: a comprehensive review of currently available biologics in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis. Open Access Rheumatol (2009) 0.75
Etanercept in the treatment of recalcitrant enteropathic arthritis: a case report. J Med Case Rep (2012) 0.75
Treatment of ankylosing spondylitis: focus on etanercept. Biologics (2007) 0.75
[Biologics in the early treatment of ankylosing spondylitis and related forms of spondyloarthritis]. Wien Med Wochenschr (2008) 0.75
The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis (2009) 8.37
Prevalence of spondylarthropathies in HLA-B27 positive and negative blood donors. Arthritis Rheum (1998) 6.16
Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet (2002) 6.12
The Assessment of SpondyloArthritis International Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general. Ann Rheum Dis (2010) 5.24
2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis (2011) 4.78
Successful treatment of active ankylosing spondylitis with the anti-tumor necrosis factor alpha monoclonal antibody infliximab. Arthritis Rheum (2000) 4.62
The Assessment of SpondyloArthritis international Society (ASAS) handbook: a guide to assess spondyloarthritis. Ann Rheum Dis (2009) 4.37
ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis (2005) 4.31
Identification of a novel bacterial sequence associated with Crohn's disease. Gastroenterology (2000) 3.90
The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part I): classification of paper patients by expert opinion including uncertainty appraisal. Ann Rheum Dis (2009) 3.32
Development of an ASAS-endorsed disease activity score (ASDAS) in patients with ankylosing spondylitis. Ann Rheum Dis (2008) 3.17
Defining active sacroiliitis on magnetic resonance imaging (MRI) for classification of axial spondyloarthritis: a consensual approach by the ASAS/OMERACT MRI group. Ann Rheum Dis (2009) 3.15
Use of immunohistologic and in situ hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitis. Arthritis Rheum (1995) 3.10
Blindsight in normal observers. Nature (1995) 3.07
Neuronal activity in human primary visual cortex correlates with perception during binocular rivalry. Nat Neurosci (2000) 2.91
Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis. Arthritis Rheum (2003) 2.91
How to diagnose axial spondyloarthritis early. Ann Rheum Dis (2004) 2.91
International ASAS consensus statement for the use of anti-tumour necrosis factor agents in patients with ankylosing spondylitis. Ann Rheum Dis (2003) 2.85
Magnetic resonance imaging examinations of the spine in patients with ankylosing spondylitis, before and after successful therapy with infliximab: evaluation of a new scoring system. Arthritis Rheum (2003) 2.78
European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies. Ann Rheum Dis (2011) 2.74
Ankylosing spondylitis: an overview. Ann Rheum Dis (2002) 2.71
Familial expression of anti-Saccharomyces cerevisiae mannan antibodies in affected and unaffected relatives of patients with Crohn's disease. Gut (2000) 2.71
Treatment benefit or survival of the fittest: what drives the time-dependent decrease in serious infection rates under TNF inhibition and what does this imply for the individual patient? Ann Rheum Dis (2011) 2.67
Results of provider self-adjudication using the prudent layperson standard compared with the managed care organization's emergency department claim review process. Ann Emerg Med (2000) 2.64
Evaluation of a novel 7-joint ultrasound score in daily rheumatologic practice: a pilot project. Arthritis Rheum (2009) 2.57
Two distinct mechanisms for redistribution of lymphocyte surface macromolecules. I. Relationship to cytoplasmic myosin. J Cell Biol (1978) 2.54
Disability and handicap in rheumatoid arthritis and ankylosing spondylitis--results from the German rheumatological database. German Collaborative Arthritis Centers. J Rheumatol (2000) 2.45
Divergent T-cell cytokine patterns in inflammatory arthritis. Proc Natl Acad Sci U S A (1994) 2.45
Diagnostic accuracy of serological assays in pediatric inflammatory bowel disease. Gastroenterology (1998) 2.38
ASDAS, a highly discriminatory ASAS-endorsed disease activity score in patients with ankylosing spondylitis. Ann Rheum Dis (2008) 2.37
HIV-1-resistance phenotype conferred by combination of two separate inherited mutations of CCR5 gene. Lancet (1998) 2.32
Efficacy and safety of infliximab plus naproxen versus naproxen alone in patients with early, active axial spondyloarthritis: results from the double-blind, placebo-controlled INFAST study, Part 1. Ann Rheum Dis (2013) 2.32
Prediction of a major clinical response (BASDAI 50) to tumour necrosis factor alpha blockers in ankylosing spondylitis. Ann Rheum Dis (2004) 2.26
New criteria for inflammatory back pain in patients with chronic back pain: a real patient exercise by experts from the Assessment of SpondyloArthritis international Society (ASAS). Ann Rheum Dis (2009) 2.22
First update of the international ASAS consensus statement for the use of anti-TNF agents in patients with ankylosing spondylitis. Ann Rheum Dis (2005) 2.21
Long-term efficacy and safety of infliximab in the treatment of ankylosing spondylitis: an open, observational, extension study of a three-month, randomized, placebo-controlled trial. Arthritis Rheum (2003) 2.20
Use of dynamic magnetic resonance imaging with fast imaging in the detection of early and advanced sacroiliitis in spondylarthropathy patients. Arthritis Rheum (1994) 2.19
Dead cell discrimination with 7-amino-actinomycin D in combination with dual color immunofluorescence in single laser flow cytometry. Cytometry (1992) 2.19
Treatment continuation in patients receiving biological agents or conventional DMARD therapy. Ann Rheum Dis (2005) 2.15
Immunoglobulin VH3 gene products: natural ligands for HIV gp120. Science (1993) 2.08
Attention activates winner-take-all competition among visual filters. Nat Neurosci (1999) 2.04
[The diagnosis of reactive arthritis. The possibilities and limits]. Dtsch Med Wochenschr (1993) 2.03
No efficacy of subcutaneous methotrexate in active ankylosing spondylitis: a 16-week open-label trial. Ann Rheum Dis (2006) 1.94
[German 2012 guidelines for the sequential medical treatment of rheumatoid arthritis. Adapted EULAR recommendations and updated treatment algorithm]. Z Rheumatol (2012) 1.91
Selectivity for polar, hyperbolic, and Cartesian gratings in macaque visual cortex. Science (1993) 1.88
Association of genotypes affecting the expression of interleukin-1beta or interleukin-1 receptor antagonist with osteoarthritis. Arthritis Rheum (2000) 1.88
Efficacy of sulfasalazine in patients with inflammatory back pain due to undifferentiated spondyloarthritis and early ankylosing spondylitis: a multicentre randomised controlled trial. Ann Rheum Dis (2006) 1.86
Radiologic diagnosis and pathology of the spondyloarthropathies. Rheum Dis Clin North Am (1998) 1.86
Quantitative analyses of sacroiliac biopsies in spondyloarthropathies: T cells and macrophages predominate in early and active sacroiliitis- cellularity correlates with the degree of enhancement detected by magnetic resonance imaging. Ann Rheum Dis (2000) 1.85
[Therapy of ankylosing spondylitis (AS) with radium chloride (224SpondylAT)]. Z Rheumatol (2001) 1.82
Persistent clinical response to the anti-TNF-alpha antibody infliximab in patients with ankylosing spondylitis over 3 years. Rheumatology (Oxford) (2005) 1.82
Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo-controlled Phase 3 study. Ann Rheum Dis (2013) 1.81
CTLA4 alanine-17 confers genetic susceptibility to Graves' disease and to type 1 diabetes mellitus. J Clin Endocrinol Metab (1997) 1.78
Importance of psychological well being and disease activity in termination of an initial DMARD therapy. J Rheumatol (1997) 1.77
Outcomes of a multicentre randomised clinical trial of etanercept to treat ankylosing spondylitis. Ann Rheum Dis (2004) 1.76
Thermochemotherapy: synergism between hyperthermia (42-43 degrees) and adriamycin (of bleomycin) in mammalian cell inactivation. Proc Natl Acad Sci U S A (1975) 1.75
[Amendment of the structural quality for inpatient rheumatology. A forward-looking concept]. Z Rheumatol (2011) 1.74
The national database of the German Collaborative Arthritis Centres: I. Structure, aims, and patients. Ann Rheum Dis (2001) 1.70
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007. Ann Rheum Dis (2007) 1.70
Current evidence for the management of ankylosing spondylitis: a systematic literature review for the ASAS/EULAR management recommendations in ankylosing spondylitis. Ann Rheum Dis (2005) 1.70